Share on StockTwits

A number of stock research firms have changed their ratings and price targets for Loxo Oncology (NASDAQ: LOXO) during the last seven days:

  • Loxo Oncology is now covered by analysts at JMP Securities. They set an “outperform” rating and a $23.00 price target on the stock.
  • Loxo Oncology is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $20.00 price target on the stock.
  • Loxo Oncology is now covered by analysts at Oppenheimer. They set an “outperform” rating and a $20.00 price target on the stock.
  • Loxo Oncology is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $20.00 price target on the stock.
  • Loxo Oncology is now covered by analysts at Cowen and Company. They set an “outperform” rating on the stock.

Shares of Loxo Oncology Inc (NASDAQ:LOXO) traded up 3.12% on Wednesday, hitting $14.23. The stock had a trading volume of 41,729 shares. Loxo Oncology Inc has a 52 week low of $12.687 and a 52 week high of $14.29. The stock has a 50-day moving average of $13.07 and a 200-day moving average of $13.07. The company’s market cap is $226.8 million.

Loxo Oncology, Inc (NASDAQ:LOXO) develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.